Barclays
STTK icon

Barclays’s Shattuck Labs STTK Stock Holding History

Barclays’s Portfolio STTK Stock Details STTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121K Sell
17,374
-102,505
-86% -$639K ﹤0.01% 3962
2026
Q1 		$771K Buy
+119,879
New +$569K ﹤0.01% 2914
2025
Q3 		– Sell
-2,114
Closed -$1.67K – 5721
2025
Q2 		$1.67K Sell
2,114
-48,771
-96% -$47.3K ﹤0.01% 5047
2025
Q1 		$48.3K Sell
50,885
-10,106
-17% -$12.5K ﹤0.01% 4620
2024
Q4 		$73.8K Buy
60,991
+6,680
+12% +$8.28K ﹤0.01% 4658
2024
Q3 		$190K Buy
54,311
+40,717
+300% +$152K ﹤0.01% 4331
2024
Q2 		$52.5K Buy
13,594
+13,402
+6,980% +$109K ﹤0.01% 4192
2024
Q1 		$1.72K Buy
+192
New +$1.76K ﹤0.01% 4922
2023
Q4 		– Sell
-16,471
Closed -$25K – 5343
2023
Q3 		$25K Hold
16,471
– – ﹤0.01% 4121
2023
Q2 		$51.4K Hold
16,471
– – ﹤0.01% 3821
2023
Q1 		$48.4K Hold
16,471
– – ﹤0.01% 4459
2022
Q4 		$37.9K Hold
16,471
– – ﹤0.01% 4646
2022
Q3 		$44K Sell
16,471
-39
-0.2% -$146 ﹤0.01% 3818
2022
Q2 		$67K Sell
16,510
-4,350
-21% -$15.8K ﹤0.01% 3934
2022
Q1 		$88K Buy
+20,860
New +$118K ﹤0.01% 3847

Other funds holding STTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
NCM
NEXTBio Capital Management Menlo Park, California $217M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's STTK Position: Q2 2026 in Review

Barclays reduced its Shattuck Labs (STTK) stake by 86% in Q2 2026, selling an estimated $639K and leaving 17,374 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #3962.

Barclays first reported a position in STTK in Q1 2022 and has held it in 15 quarters since. The position peaked at $771K in Q1 2026. 100 funds tracked by Wall St. Rank hold STTK as of Q2 2026.

  • Barclays held 17,374 shares of Shattuck Labs worth $121K as of Q2 2026.
  • Barclays sold 102,505 Shattuck Labs shares in Q2 2026, an estimated $639K.
  • Shattuck Labs made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3962 holding.
  • Barclays first reported a position in Shattuck Labs in Q1 2022 and has held it in 15 quarters since.
  • Barclays's Shattuck Labs position peaked at $771K in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Shattuck Labs as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.